| P2093 | author name string | Albert J Czaja | |
| P2860 | cites work | Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic Hepatitis | Q28248157 |
| | Mycophenolate mofetil--is it worth the cost? The in-favor opinion | Q33652719 |
| | Immunosuppressive drugs: the first 50 years and a glance forward | Q33908046 |
| | Mycophenolate mofetil and its mechanisms of action | Q33957177 |
| | Budesonide induces complete remission in autoimmune hepatitis | Q34012678 |
| | Diagnosis and management of autoimmune hepatitis | Q34118165 |
| | Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. | Q51035941 |
| | Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. | Q53160616 |
| | Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. | Q53888400 |
| | Oral budesonide for treatment of autoimmune chronic active hepatitis | Q54020669 |
| | Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. | Q54034536 |
| | Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. | Q54190784 |
| | Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis | Q71039699 |
| | Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis | Q71428816 |
| | Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis | Q73130778 |
| | Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis | Q79798205 |
| | Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease | Q80720176 |
| | Safety issues in the management of autoimmune hepatitis | Q81230534 |
| | Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment | Q82824269 |
| | The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes | Q84348272 |
| | Animal models of autoimmune hepatitis | Q84633053 |
| | Controlled trial of prednisone and azathioprine in active chronic hepatitis | Q93735616 |
| | Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy | Q34286525 |
| | Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial | Q34498312 |
| | Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis | Q35621266 |
| | Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. | Q36180465 |
| | Cost-effectiveness of pharmacotherapy for autoimmune hepatitis | Q36376398 |
| | Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection | Q36699786 |
| | The use of budesonide in the treatment of autoimmune hepatitis in Canada | Q37139335 |
| | A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis | Q37202406 |
| | Current and future treatments of autoimmune hepatitis | Q37503380 |
| | Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis | Q37682722 |
| | Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis | Q37745609 |
| | Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis | Q37929255 |
| | Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis | Q40198730 |
| | Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis | Q42989153 |
| | Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis | Q43225448 |
| | Cyclosporine treatment of autoimmune chronic active hepatitis | Q43450453 |
| | Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience | Q43645710 |
| | Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis | Q43645960 |
| | Autoimmune hepatitis: the dilemma of rare diseases | Q43837229 |
| | Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis | Q43933947 |
| | Cyclosporin, a new treatment for autoimmune chronic active hepatitis | Q44144947 |
| | A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens | Q44825298 |
| | Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy | Q44902465 |
| | Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis | Q45057464 |
| | Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. | Q45963125 |
| | Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. | Q46009237 |
| | Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree. | Q46009238 |
| | Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. | Q46197799 |
| | Mycophenolate mofetil for autoimmune hepatitis: a single practice experience | Q46198163 |
| | Mycophenolate mofetil as second line therapy in autoimmune hepatitis? | Q46317682 |
| | Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis | Q46422178 |
| | Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus | Q46584599 |
| | Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease | Q46689681 |
| | Budesonide in previously untreated autoimmune hepatitis. | Q46702694 |
| | A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis | Q46808954 |
| | Rapidity of treatment response and outcome in type 1 autoimmune hepatitis | Q47787859 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autoimmune hepatitis | Q786844 |
| P304 | page(s) | 615-620 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | Canadian Journal of Gastroenterology | Q15749648 |
| P1476 | title | Autoimmune hepatitis: focusing on treatments other than steroids | |
| P478 | volume | 26 | |